Sunday, 18 February 2018

Pfizer and Merck KGaA suffered another setback with immuno-oncology med Bavencio

Pfizer and Merck KGaA have suffered another setback with immuno-oncology med Bavencio—and this one’s raising some eyebrows.
Thursday, the companies revealed Bavencio (avelumab) had failed to outdo chemo at extending the lives of second-line lung cancer patients with PD-L1-positive tumors. And the way Evercore ISI analyst Umer Raffat sees it, there’s no “good reason” to explain the flop.

No comments:

Post a Comment

More exercise leads to more youthful arteries

According to US research exercising two to three times a week (30 minutes per session) over a lifetime led to more youthful middle-sized ar...